Omidenepag Isopropyl Patent Expiration

Omidenepag Isopropyl is Used for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Visiox Pharma Llc in its drug Omlonti on Sep 22, 2022.


Omidenepag Isopropyl Patents

Given below is the list of patents protecting Omidenepag Isopropyl, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Omlonti US11666563 Pharmaceutical preparation containing pyridyl aminoacetic acid compound Jul 16, 2039 Visiox Pharma
Omlonti US10774072 Crystal of N-substituted sulfonamide compound Jun 10, 2035 Visiox Pharma
Omlonti US10179127 Pharmaceutical formulations comprising a pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti US10702511 Pharmaceutical formulations comprising a pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti US10765750 Pharmaceutical composition containing pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti US11197849 Pharmaceutical formulations comprising a pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti US11793798 Pharmaceutical formulations comprising a pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti US9415038 Pharmaceutical formulations comprising a pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti USRE48183 Pharmaceutical formulations comprising a pyridylaminoacetic acid compound Jan 08, 2035 Visiox Pharma
Omlonti US8648097 Pyridylaminoacetic acid compound Oct 13, 2029 Visiox Pharma
Omlonti US8685986 Medical composition for treatment or prophylaxis of glaucoma Oct 13, 2029 Visiox Pharma



Omidenepag Isopropyl's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List